IL6 and adenocarcinoma: Chromatin immunoprecipitation assays in tumors showed that BRD4 is recruited at the IL6 promoter and that (+)-JQ1 treatment impairs BRD4 occupancy, suggesting that (+)-JQ1 plays a primary role in hindering IL6 expression in C26 adenocarcinoma tumors (Fig. 5d).